BioNTech Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . BioNTech SE
BNTX Stock  USD 117.20  1.19  1.01%   
BioNTech financial statements provide useful quarterly and yearly information to potential BioNTech SE investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioNTech financial statements helps investors assess BioNTech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioNTech's valuation are summarized below:
Gross Profit
16.1 B
Profit Margin
(0.15)
Market Capitalization
28.1 B
Enterprise Value Revenue
3.3497
Revenue
3 B
We have found one hundred twenty available fundamental signals for BioNTech SE, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioNTech SE prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 24.4 B in 2024, whereas Enterprise Value is likely to drop slightly above 7.7 B in 2024.

BioNTech Total Revenue

6.43 Billion

Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0111 or PTB Ratio of 1.2. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Check out the analysis of BioNTech Correlation against competitors.

BioNTech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets24.2 B23 B6.2 B
Slightly volatile
Short and Long Term Debt Total162.4 M219.1 M100.2 M
Slightly volatile
Other Current Liabilities751.8 M1.2 B420.2 M
Slightly volatile
Total Current Liabilities1.3 B2.1 B749.8 M
Slightly volatile
Property Plant And Equipment Net1 B971.6 M296.6 M
Slightly volatile
Current Deferred Revenue371 M353.3 M123.5 M
Slightly volatile
Accounts Payable371.7 M354 M90 M
Slightly volatile
Cash12.2 B11.7 B2.9 B
Slightly volatile
Non Current Assets Total3.7 B3.5 B735.2 M
Slightly volatile
Cash And Short Term Investments17.4 B16.5 B3.6 B
Slightly volatile
Net Receivables3 B2.2 B1.7 B
Slightly volatile
Good Will380.6 M362.5 M61.6 M
Slightly volatile
Common Stock Total Equity185.2 M283.3 M121.5 M
Slightly volatile
Short Term Investments5.1 B4.9 B715.7 M
Slightly volatile
Liabilities And Stockholders Equity24.2 B23 B6.2 B
Slightly volatile
Non Current Liabilities Total378.2 M689.9 M329.2 M
Slightly volatile
Inventory190.9 M357.7 M106.6 M
Slightly volatile
Other Current Assets483 M460 M115.8 M
Slightly volatile
Total Liabilities1.7 B2.8 B1.1 B
Slightly volatile
Property Plant And Equipment Gross1.2 B1.2 B330.4 M
Slightly volatile
Total Current Assets20.5 B19.5 B5.5 B
Slightly volatile
Short Term Debt37.6 M56.2 M22 M
Slightly volatile
Intangible Assets820.8 M781.7 M156.5 M
Slightly volatile
Common Stock218 M285.9 M124 M
Slightly volatile
Net Working Capital18.3 B17.5 B4.6 B
Slightly volatile
Capital Stock259.5 M285.9 M217.2 M
Slightly volatile

BioNTech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income375.5 M357.6 M72.5 M
Slightly volatile
Depreciation And Amortization192.6 M183.4 M50.2 M
Slightly volatile
Interest Expense7.5 M7.9 M7.6 M
Slightly volatile
Selling General Administrative519.8 M495 M141.3 M
Slightly volatile
Selling And Marketing Expenses65.8 M62.7 M20.8 M
Slightly volatile
Total Revenue6.4 B3.8 B3.2 B
Slightly volatile
Other Operating Expenses2 B3.1 B1.1 B
Slightly volatile
Research Development1.9 B1.8 B371.5 M
Slightly volatile
Cost Of Revenue569.8 M599.8 M761.7 M
Slightly volatile
Reconciled Depreciation192.6 M183.4 M50.2 M
Slightly volatile

BioNTech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation51.8 M51.4 M28.2 M
Slightly volatile
Begin Period Cash Flow14.6 B13.9 B2.3 B
Slightly volatile
Depreciation192.6 M183.4 M50.2 M
Slightly volatile
Capital Expenditures740.8 M705.5 M176.7 M
Slightly volatile
End Period Cash Flow12.2 B11.7 B2.9 B
Slightly volatile
Change To Netincome1.5 B1.4 B384.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.776.072931.9801
Slightly volatile
Dividend Yield0.01110.01250.0136
Slightly volatile
Days Sales Outstanding10820696.7291
Slightly volatile
Stock Based Compensation To Revenue0.01280.01350.0807
Slightly volatile
Capex To Depreciation3.413.84684.2342
Slightly volatile
EV To Sales2.923.076129.8814
Slightly volatile
Inventory Turnover1.591.676818.3876
Slightly volatile
Days Of Inventory On Hand22921847.5181
Slightly volatile
Payables Turnover1.611.69445.7742
Slightly volatile
Sales General And Administrative To Revenue0.210.12960.2742
Slightly volatile
Research And Ddevelopement To Revenue0.440.46691.1045
Slightly volatile
Capex To Revenue0.180.18470.6171
Slightly volatile
Cash Per Share71.5468.131414.8039
Slightly volatile
Payout Ratio0.04030.04540.0494
Slightly volatile
Days Payables Outstanding226215151
Slightly volatile
Income Quality4.764.52861.1807
Slightly volatile
Intangibles To Total Assets0.08810.04970.0601
Pretty Stable
Current Ratio9.99.43125.4647
Slightly volatile
Receivables Turnover1.681.76768.3278
Slightly volatile
Graham Number66.4484.751443.8181
Slightly volatile
Debt To Equity0.0090.00940.0172
Pretty Stable
Capex Per Share3.052.90450.7409
Slightly volatile
Revenue Per Share19.2115.722612.6101
Slightly volatile
Interest Debt Per Share0.420.81890.2716
Slightly volatile
Debt To Assets0.00790.00830.0109
Pretty Stable
Operating Cycle445424120
Slightly volatile
Days Of Payables Outstanding226215151
Slightly volatile
Dividend Payout Ratio0.04030.04540.0494
Slightly volatile
Ebt Per Ebit1.01.7181.3057
Pretty Stable
Long Term Debt To Capitalization0.00890.00930.1079
Slightly volatile
Total Debt To Capitalization0.00890.00930.0154
Pretty Stable
Debt Equity Ratio0.0090.00940.0172
Pretty Stable
Quick Ratio9.729.25845.3773
Slightly volatile
Cash Ratio5.915.63334.2913
Slightly volatile
Days Of Inventory Outstanding22921847.5181
Slightly volatile
Days Of Sales Outstanding10820696.7291
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.830.86872.0769
Pretty Stable
Fixed Asset Turnover7.473.93065.141
Slightly volatile
Debt Ratio0.00790.00830.0109
Pretty Stable
Price Sales Ratio5.776.072931.9801
Slightly volatile
Asset Turnover0.320.1660.2855
Slightly volatile

BioNTech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap24.4 B23.2 B10.8 B
Slightly volatile
Enterprise Value7.7 B11.7 B6.9 B
Slightly volatile

BioNTech Fundamental Market Drivers

Forward Price Earnings7.0373
Cash And Short Term Investments16.5 B

BioNTech Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue353.3 M371 M
Total Revenue3.8 B6.4 B
Cost Of Revenue599.8 M569.8 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.13  0.21 
Research And Ddevelopement To Revenue 0.47  0.44 
Capex To Revenue 0.18  0.18 
Revenue Per Share 15.72  19.21 
Ebit Per Revenue 0.18  0.19 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY